HRCM
IMVT icon

Hood River Capital Management’s Immunovant IMVT Stock Holding History

Hood River Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48K Hold
100
– – ﹤0.01% 167
2025
Q4 		$2.54K Hold
100
– – ﹤0.01% 175
2025
Q3 		$1.61K Hold
100
– – ﹤0.01% 153
2025
Q2 		$1.6K Sell
100
-1,175,763
-100% -$17.8M ﹤0.01% 148
2025
Q1 		$20.1M Buy
1,175,863
+30,245
+3% +$633K 0.34% 91
2024
Q4 		$28.4M Buy
1,145,618
+2,051
+0.2% +$58.2K 0.42% 91
2024
Q3 		$32.6M Buy
+1,143,567
New +$33.7M 0.53% 72

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Hood River Capital Management's IMVT Position: Q1 2026 in Review

Hood River Capital Management held its Immunovant (IMVT) position steady in Q1 2026 at 100 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #167.

Hood River Capital Management first reported a position in IMVT in Q3 2024 and has held it in 7 quarters since. The position peaked at $32.6M in Q3 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Hood River Capital Management held 100 shares of Immunovant worth $2.48K as of Q1 2026.
  • Hood River Capital Management left its Immunovant share count unchanged in Q1 2026.
  • Immunovant made up ﹤0.01% of Hood River Capital Management's portfolio in Q1 2026, its #167 holding.
  • Hood River Capital Management first reported a position in Immunovant in Q3 2024 and has held it in 7 quarters since.
  • Hood River Capital Management's Immunovant position peaked at $32.6M in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.